Moreover, it could regulate the PTEN/AKT signalling pathway in myeloma and43 breast cancer.44 Thus, we further explored whether SLC25A5‐AS1 could directly interact with miR‐19a‐3p via the PTEN/PI3K/AKT pathway to regulate tumour progression. Here, SLC25A5 is linked to plasma cell myeloma.